ResMed Inc. (RMD) falls sharply after its fiscal Q4 earnings release, even as revenue hit a record and EPS rose. Investors are weighing strong sales growth against softer operating margin and weaker free cash flow, which raised questions about whether the stock’s prior valuation was too rich.
ResMed Inc. (RMD) falls 10.6% in extended-hours trading after its fiscal Q4 2026 earnings release, as investors focus less on record revenue and more on softer operating margin and a 21% drop in free cash flow. The stock’s decline suggests the market wanted cleaner execution at an already elevated valuation, and it means investors should now judge RMD on whether growth and cash generation can reaccelerate from here.
ResMed Inc. (RMD) falls sharply in extended-hours trading, dropping from the prior regular-session close of $223.24 to $199.50, a decline of 10.63%. The move follows ResMed’s fiscal Q4 2026 earnings announcement, while regular-session trading will confirm whether the after-hours drop holds.
Key Takeaways
RMD fell 10.63% in extended-hours trading, moving from $223.24 to $199.50.
The clearest catalyst is the Aug. 6 fiscal Q4 2026 earnings announcement, not retail-trader speculation.
Revenue reached a record $1.5B, while non-GAAP EPS rose 16% to $2.95.
Gross margin improved, but operating margin slipped and free cash flow fell 21% year over year.
The selloff changes the entry price, but investors still need evidence that growth and cash generation can support the valuation.
What Is Behind ResMed Inc. (RMD)’s After-Hours Selloff
The most likely catalyst is ResMed’s fiscal Q4 2026 earnings event. The company scheduled the results for Aug. 6, 2026, after the NYSE close, followed by a 4:30 p.m. ET webcast. That timing matches the sharp repricing in RMD.
The headline numbers were not a simple earnings disaster. ResMed reported Q4 revenue of $1.5B, up 9% year over year and a record for the company. GAAP diluted EPS increased 2% to $2.64, while non-GAAP diluted EPS climbed 16% to $2.95.
However, one contemporaneous earnings summary placed revenue at $1.46B, in line with the $1.46B analyst estimate. The same summary said non-GAAP EPS beat consensus by $0.06. In other words, RMD delivered solid growth and a modest earnings beat, but revenue did not exceed expectations. That combination can pressure a stock when investors had already priced in strong execution.
A same-day KeyBanc action added a second pressure point. KeyBanc lowered its ResMed price target from $260 to $255. Still, the earnings event remains the primary catalyst because it occurred immediately before the decline, while the target cut looks more like a follow-on adjustment.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
How ResMed’s Q4 Results Explain the RMD Stock Reaction
ResMed’s Q4 results show a business that continues to grow, but the quality of that growth produced mixed signals. Non-GAAP gross margin reached 62.3%, an improvement of 90 basis points from the prior year. That gain points to healthy product economics and operating leverage in parts of the business.
The operating line was less impressive. Non-GAAP operating margin came in at 35.2%, down 10 basis points year over year. Free cash flow totaled $404M, down 21% from the prior-year quarter. For a mature medical technology company, weaker cash generation can matter as much as a small EPS beat. Earnings can look polished while cash flow tells a more demanding story.
Capital returns remain a clear strength. ResMed returned $1.0B to shareholders through buybacks and dividends during fiscal 2026, an increase of more than 70%. That support can help per-share results, but it does not remove the need for sustained revenue growth and healthy cash conversion.
The immediate lesson is simple: RMD did not collapse because revenue stopped growing. The stock fell because a 9% revenue increase, a modest EPS beat, lower operating margin, and weaker free cash flow did not create a clean enough picture for shareholders at the prior price.
ResMed Inc. (RMD) Valuation and Competitive Position After the Drop
At the $199.50 extended-hours print, ResMed carries a market capitalization of $32.38B and a trailing P/E ratio of 21.59. Its dividend yield is 1.04%. The valuation is lower than before the earnings reaction, but the stock still trades above its 52-week low of $180.27 and well below its 52-week high of $291.5684.
ResMed’s competitive position rests on more than selling breathing devices. The company says it has more than 15 million cloud-connectable devices in its network. Its ecosystem combines machines, masks, tubing, and the myAir app, creating a link between hardware, patient adherence, and remote care.
Recurring products also matter. Masks, diagnostic products, and accessories represented roughly 36% of fiscal 2025 revenue, up from 35% in fiscal 2024 and 34% in fiscal 2023. This mix gives ResMed a replacement cycle alongside its device sales. It also supports customer retention when providers and patients use connected equipment and digital tools together.
Competition and reimbursement remain real risks. ResMed operates in sleep apnea and respiratory care, where demand depends on diagnosis, insurance coverage, replacement schedules, and competing device platforms. The planned sale of MatrixCare to Frazier Healthcare Partners, announced July 7, is expected to close in the first quarter of fiscal 2027, subject to approvals and customary conditions. That transaction could sharpen the company’s focus on sleep and breathing health, but it also makes portfolio execution more important.
What RMD Investors Should Do After the Earnings Decline
The first step is to separate price damage from business damage. The $199.50 print reflects a fast extended-hours repricing. It does not, by itself, prove that ResMed’s competitive moat has weakened. Regular-session trading provides the next confirmed price test.
The second step is to track the balance between growth and profitability. The strongest figures are 9% revenue growth, a 62.3% gross margin, and 16% non-GAAP EPS growth. The caution flags are the 10-basis-point operating-margin decline and 21% free-cash-flow decline. A recovery case becomes stronger if revenue growth continues while operating margin and cash flow improve.
The third step is valuation discipline. Analyst targets show a consensus of $241, with a low of $220 and a high of $300. The broader analyst rating is Hold, with 14 Buy ratings, 16 Holds, and 5 Sell ratings. Those figures frame the debate, but they do not replace the operating data. A $199.50 price can offer more downside protection than $223.24, yet the investment case still depends on cash generation and execution.
ResMed Inc. (RMD) falls because its latest earnings print delivered solid growth without a clear upside surprise in revenue, while margins and free cash flow raised fresh concerns. The selloff improves the valuation setup, but disciplined investors should treat the stock as a recovery candidate only if growth, profitability, and cash conversion reinforce one another in regular trading and future results.
RMD is down because investors reacted negatively to ResMed’s Q4 earnings mix: revenue grew and EPS beat, but operating margin slipped and free cash flow fell sharply. The after-hours selloff also suggests the market had already priced in strong results.
+Should I buy RMD stock now?
The drop improves the entry price, but the article does not support an aggressive buy based on one earnings report alone. Investors should wait for evidence that revenue growth, margins, and cash flow can all improve before adding heavily.
+Did ResMed miss earnings expectations?
Not clearly. The article says non-GAAP EPS beat consensus, while revenue was roughly in line with estimates rather than a major beat. That was enough to disappoint investors who expected a stronger overall print.
+What matters most for RMD investors after this selloff?
The key issue is whether ResMed can keep growing while improving operating margin and free cash flow. If those trends stabilize, the lower share price could look more attractive; if not, the valuation may still be vulnerable.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on RMD?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
